Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IPA 
Immunoprecise Antibodies Ltd (IPA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: IPA (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 208.21% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 88.33M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 2 | Beta 0.22 | 52 Weeks Range 0.27 - 2.32 | Updated Date 07/17/2025 |
52 Weeks Range 0.27 - 2.32 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -194.79% | Operating Margin (TTM) -53.47% |
Management Effectiveness
Return on Assets (TTM) -14.88% | Return on Equity (TTM) -124.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 88336153 | Price to Sales(TTM) 3.68 |
Enterprise Value 88336153 | Price to Sales(TTM) 3.68 | ||
Enterprise Value to Revenue 5.05 | Enterprise Value to EBITDA -4.68 | Shares Outstanding 45765100 | Shares Floating 41560677 |
Shares Outstanding 45765100 | Shares Floating 41560677 | ||
Percent Insiders 5.21 | Percent Institutions 8.59 |
Upturn AI SWOT
Immunoprecise Antibodies Ltd
Company Overview
History and Background
Immunoprecise Antibodies Ltd. (IPA) was founded in 1989. It has evolved from a contract research organization to a biotherapeutics discovery company specializing in antibody discovery and development. Over time, it has expanded its technology platforms and service offerings.
Core Business Areas
- Antibody Discovery: Provides custom antibody discovery services, including hybridoma technology, B cell cloning, and phage display.
- Antibody Engineering: Offers antibody optimization, humanization, and antibody engineering services to improve antibody properties.
- In Vitro and In Vivo Services: Conducts in vitro and in vivo studies to evaluate antibody efficacy and safety.
- Biomanufacturing: Offers small-scale biomanufacturing services for antibody production.
Leadership and Structure
The leadership team includes Jennifer Bath (President & CEO). The company has a board of directors overseeing its operations and strategic direction. It operates with a functional structure, with departments focused on antibody discovery, engineering, and related services.
Top Products and Market Share
Key Offerings
- Custom Antibody Discovery: Custom antibody discovery services utilizing various platforms. Competitors include AbCellera, Twist Bioscience, and Ligand Pharmaceuticals. Market share data is not readily available.
- Phage Display Antibody Libraries: High-diversity phage display antibody libraries. Competitors include Creative Biolabs. Market share data is not readily available.
- Hybridoma Antibody Production: Traditional hybridoma technology for antibody generation. Competitors include Thermo Fisher Scientific and GenScript. Market share data is not readily available.
- In Vivo Services: Provides in vivo antibody efficacy and safety testing in animal models. Competitors include Charles River Laboratories. Market share data is not readily available.
Market Dynamics
Industry Overview
The antibody discovery and development market is growing due to increased demand for novel biotherapeutics. Key drivers include advancements in technology, rising prevalence of chronic diseases, and growing investment in R&D.
Positioning
Immunoprecise is positioned as a provider of comprehensive antibody discovery and development services, leveraging multiple technology platforms. It aims to offer a one-stop solution for antibody development.
Total Addressable Market (TAM)
The global antibody market is projected to reach hundreds of billions USD in the next decade. IPA is positioned to capture a portion of this market through its comprehensive service offerings.
Upturn SWOT Analysis
Strengths
- Diverse technology platforms
- Comprehensive service offerings
- Experienced scientific team
- Strong focus on innovation
Weaknesses
- Limited brand recognition
- Smaller scale compared to larger competitors
- Reliance on service contracts
- History of losses
Opportunities
- Expanding into new therapeutic areas
- Forming strategic partnerships
- Acquiring complementary technologies
- Increasing demand for antibody therapeutics
Threats
- Competition from larger CROs
- Technological disruptions
- Economic downturns
- Regulatory changes
Competitors and Market Share
Key Competitors
- ABCL
- TWST
- LIGD
Competitive Landscape
Immunoprecise faces competition from larger and more established CROs and biopharmaceutical companies. It differentiates itself through its diverse technology platforms and comprehensive service offerings.
Major Acquisitions
BioStrand
- Year: 2022
- Acquisition Price (USD millions): 14.5
- Strategic Rationale: Expanded IPAs AI capabilities through BioStrands AI based solutions.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been uneven, with periods of rapid expansion and periods of slower growth or losses.
Future Projections: Future growth is dependent on the company's ability to secure new contracts, develop new technologies, and expand its market presence. Analyst projections are variable and should be assessed by reviewing their analysis.
Recent Initiatives: Recent initiatives include expanding its antibody discovery platforms, forming strategic partnerships, and focusing on high-growth therapeutic areas.
Summary
Immunoprecise Antibodies is a smaller player in a competitive market with diverse technology. Its growth depends on securing contracts, developing new tech, and expanding its market presence. IPA struggles with profitability and limited brand awareness. It faces threats from larger competitors and technological disruptions, and recent acquistions have been made to help growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-party Market Research Reports
- Financial News Outlets
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immunoprecise Antibodies Ltd
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2017-01-03 | CEO, President & Non-Independent Director Dr. Jennifer Lynne Bath Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 72 | Website https://www.ipatherapeutics.com |
Full time employees 72 | Website https://www.ipatherapeutics.com | ||
ImmunoPrecise Antibodies Ltd. operates as a techbio company. It leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies; and support the discovery and development of therapeutic antibodies. The company's contract research organizations services include B cell Select platforms that enable antibody screening directly from B cells, facilitating the analysis of a set of antibodies, as well as for screening compared to traditional technologies; phage display services that are based on building custom immune libraries from various species; DeepDisplay, a technology utilizing a combination of transgenic animal platforms; bispecific Abthena technology; antibody humanization services; affinity maturation services; antibody development services; protein manufacturing; and cell line development services of target proteins or antibodies. It is also involved in the development and licensing of antibody discovery platforms and related IP assets. The company was founded in 1983 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.